LOGIN  |  REGISTER
C4 Therapeutics

BUY $CCCC

Buy $CCCC on Charles Schwab

Buy $CCCC on ETrade

Buy $CCCC on Public.com

Buy $CCCC on Fidelity

Buy $CCCC on  Robinhood

Buy $CCCC on Webull

C4 Therapeutics to Participate in Upcoming September Investor Conferences

August 29, 2024 | Last Trade: US$6.32 0.12 -1.86

TOPLINE SUMMARY

• C4 Therapeutics, Inc. will participate in fireside chats at two September investor conferences.
• The Wells Fargo Healthcare Conference is taking place in Boston, MA.
• The event will take place on September 5, 2024, at 8:45 AM ET.

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences.

Fireside Chat Details:

Event: Wells Fargo Healthcare Conference taking place in Boston, MA
Date/Time: September 5, 2024 at 8:45 AM ET

Event: 2024 Cantor Global Healthcare Conference taking place in New York, New York
Date/Time: September 18, 2024 at 8:35 AM ET

Live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com. Archived replays of the webcasts will be available for approximately 30 days following the live events.

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
This email address is being protected from spambots. You need JavaScript enabled to view it. 

BUY $CCCC

Buy $CCCC on Charles Schwab

Buy $CCCC on ETrade

Buy $CCCC on Public.com

Buy $CCCC on Fidelity

Buy $CCCC on  Robinhood

Buy $CCCC on Webull

Stock Quote

BUY $CCCC

Buy $CCCC on Charles Schwab

Buy $CCCC on ETrade

Buy $CCCC on Public.com

Buy $CCCC on Fidelity

Buy $CCCC on  Robinhood

Buy $CCCC on Webull

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE
C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB